estenose aórtica

Highlights TCT 2019

TCT 2019 | PARTNER 3: Obvious Short-Term Quality of Life Improvement, but What Happens Afterwards?

Courtesy of SBHCI. Patients with severe aortic stenosis and low surgical risk showed decreased mortality, stroke, and heart failure hospitalization at one year with transcatheter aortic valve replacement compared with surgery. Improved quality of life may seem an obvious consequence, but until now that was mere speculation. This work, presented at the TCT 2019 Scientific Sessions<a href="https://solaci.org/en/2019/10/01/tct-2019-partner-3-health-status-outcomes-from-a-randomized-trial-of-transcatheter-vs-surgical-aortic-valve-replacement-in-patients-with-severe-aortic-stenosis-at-low-surgical-risk/" title="Read more" >...</a>

TCT 2019 | PARTNER 2A at 5 Years: In Intermediate-Risk Patients, TAVR Is Still Head-to-Head with Surgery

Courtesy of the SBHCI. The 2-year results of the PARTNER 2A trial showed that transcatheter aortic valve implantation has a result similar to that of surgery in patients with aortic stenosis and intermediate surgical risk. We lacked long-term data, both clinical and related to prosthesis function. Now, at TCT 2019, researchers presented the 5-year data for this<a href="https://solaci.org/en/2019/10/01/tct-2019-partner-2a-5-year-outcomes-from-a-randomized-trial-of-transcatheter-vs-surgical-aortic-valve-replacement-in-intermediate-risk-patients-with-severe-aortic-stenosis/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | PORTICO: This vs. Any Other Valve Available in the Market

Courtesy of SBHCI. This work, presented at the TCT 2019 Scientific Sessions, showed the 30-day safety and 1-year efficacy of self-expanding prosthesis Portico compared with all valves approved by the US Food and Drug Administration (FDA) for the treatment of patients with severe aortic stenosis and high surgical risk. Between 2014 and 2019, researchers enrolled 750 patients<a href="https://solaci.org/en/2019/09/30/tct-2019-portico-a-randomized-trial-of-portico-vs-commercially-available-transcatheter-aortic-valves-in-patients-with-severe-aortic-stenosis/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | SCOPE I: Self-Expanding Valve Acurate Neo Head to Head with Sapien 3

Courtesy of SBHCI. This work, which was presented during the TCT 2019 Scientific Sessions and simultaneously published in the Lancet, randomized patients to the ACURATE Neo prosthesis (n = 373) vs. the SAPIEN 3 (n = 367) in a head-to-head comparison involving 20 European sites. Transfemoral access was used in all patients. The study had a noninferiority design, and its primary<a href="https://solaci.org/en/2019/09/30/tct-2019-scope-i-a-randomized-trial-of-the-acurate-neo-vs-the-sapien-3-bioprosthesis-in-patients-with-severe-aortic-stenosis/" title="Read more" >...</a>

Top